Cancer Drug May Not Get A Chance Due to Lack of Patent

Researchers at the University of Alberta Department of Medicine have shown that an existing small, relatively non-toxic molecule, dichloroacetate, causes regression in several different cancers. But there’s a catch: the drug isn’t patented, and pharmaceutical companies may not be interested in funding further research if the treatment won’t make them a profit. In findings that astounded the researchers, the molecule known as DCA was shown to shrink lung, breast and brain tumours in both animal and human tissue experiments

Share this Story
Load More Related Articles
Load More By Red Wolf
Load More In Health

Leave a Reply

Your email address will not be published. Required fields are marked *

Photos from Flickr